Could a common drug keep bladder cancer away?
NCT ID NCT04375813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one year. Researchers will track cancer recurrence, quality of life, and physical and mental function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
encapsulated rapamycin (eRapa)
What this could lead to
If it works, this could offer a new way to prevent bladder cancer from coming back, reducing the need for repeated surgeries or treatments.
What could go wrong
This is a mid-stage trial with 166 participants, so results may not apply to everyone. The drug may not improve recurrence rates, and side effects like immune suppression are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UT Health San Antonio
San Antonio, Texas, 78229, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States